Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma ...
In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.
Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results